Sheran Sharafi

Sheran is an associate in the Global Corporate (US) Group in Reed Smith’s New York office. Her practice currently involves representing public companies in mergers and acquisitions, securities offerings, corporate governance, and ’34 Act reporting and compliance matters.

Experience

Representative matters

Aerovate Therapeutics, Inc. (Nasdaq: AVTE) in its reverse merger with Jade Biosciences, Inc. and the $300 million concurrent financing (advised on prior to joining Reed Smith)

Scienture LLC in its business combination with TRxADE Health Inc. (Nasdaq: MEDS) (advised on prior to joining Reed Smith)

AVROBIO, Inc. (Nasdaq: AVRO) in its reverse merger with Tectonic Therapeutic, including contingent value rights (CVRs) and the concurrent private placement financing (advised on prior to joining Reed Smith)

Aerovate Therapeutics, Inc. (Nasdaq: AVTE) in its reverse merger with Jade Biosciences, Inc. and the $300 million concurrent financing (advised on prior to joining Reed Smith)

Scienture LLC in its business combination with TRxADE Health Inc. (Nasdaq: MEDS) (advised on prior to joining Reed Smith)

Immunome Inc. (Nasdaq: IMNM) in its acquisition of certain assets of Atreca, Inc. (Nasdaq: BCEL) for $5.5 million upfront cash plus contingent value rights (CVRs) (advised on prior to joining Reed Smith)

EryDel in its cross-border sale to Quince Therapeutics (Nasdaq: QNCX) (advised on prior to joining Reed Smith)

Arrowroot Acquisition Corp. (Nasdaq: ARRW) in its business combination with iLearningEngines (advised on prior to joining Reed Smith)

Graphite Bio, Inc. (Nasdaq: GRPH) in its reverse merger with LENZ Therapeutics and $53.5 million concurrent private placement financing (advised on prior to joining Reed Smith)

BioSight Ltd., an Israeli company, in its merger with Ayala Pharmaceuticals, Inc. (OTCQX: ADXS) (advised on prior to joining Reed Smith)

Ikena Oncology Inc. (Nasdaq: IKNA) in its acquisition of Pionyr Immunotherapeutics in an all-stock transaction and contingent value rights (CVRs) (advised on prior to joining Reed Smith)

AVROBIO Inc. (Nasdaq: AVRO) in its sale of its Cystinosis gene therapy program for $87.5 million to Novartis (NYSE: NVS) (advised on prior to joining Reed Smith)

TCR² Therapeutics (Nasdaq: TCRR) in its cross-border, all-stock combination with Adaptimmune Therapeutics (Nasdaq: ADAP) (advised on prior to joining Reed Smith)

Concert Pharmaceuticals (Nasdaq: CNCE) in its sale to Sun Pharma for $576 million in upfront cash plus contingent value rights (CVRs) (advised on prior to joining Reed Smith)

BJ’s Wholesale Group (NYSE: BJ) in its acquisition of assets and operations of four distribution centers and the related private transportation fleet from Burris Logistics (advised on prior to joining Reed Smith)

Vaccitech plc (Nasdaq: VACC) in its $40 million acquisition of Avidea Technologies, Inc. (advised on prior to joining Reed Smith)

Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL) in its $2.26 billion sale to Pfizer Inc. (NYSE: PFE) (advised on prior to joining Reed Smith)

KushCo Holdings, Inc. (OTCQX: KSHB) in its merger with Greenlane Holdings, Inc. (Nasdaq: GNLN)

Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) in its reverse merger with Qualigen, Inc.

Venus Concept, Inc. in its reverse merger with Restoration Robotics, Inc. (Nasdaq: HAIR)

Private company in the fashion industry in its $500 million acquisition of another fashion company and label

Recognitions

Recognized as a New York Metro Rising Star by Super Lawyers in 2022-2025

Credentials

Education

Boston University School of Law, 2016, J.D., International Law Journal - Senior Article Editor
Brooklyn College, 2013, B.A., Political Science and Government, Phi Beta Kappa; Presidential Scholarship; Peter Vallone Merit Scholarship; Rosen Fellowship